|drug3393||Telehealth monitoring Wiki||1.00|
There is one clinical trial.
This study will evaluate the antihelmintic drug, Niclosamide, as a potential treatment for mild to moderate coronavirus disease 2019 (COVID-19).
Description: Oropharangeal swabsMeasure: Change in respiratory viral clearance (by PCR) Time: Days 3 and 10
Description: Fecal swabsMeasure: Fecal viral clearance (by PCR) Time: Day 14
Description: Oropharngeal swabsMeasure: Reduction (change) in respiratory viral shedding (by PCR) Time: Days 1,3,7,10,14
Description: Fecal swabsMeasure: Reduction (change) in GI viral shedding (by PCR) Time: Days 1,3,7,10,14, 21
Description: Defined as 1) O2 saturation <92% on room air (in two consecutive measurements at least 2 hours apart) OR 2) requirement of hospitalization OR 3) need for artificial ventilation OR 4) death.Measure: Progression to severe COVID-19 Disease Time: Enrollment through final day of participation
Description: DaysMeasure: Time to resolution of a fever Time: Enrollment through final day of participation
Description: Composite counts by Adverse Events and Serious Adverse EventsMeasure: Incidence of Adverse Events (AEs) Time: Enrollment through 30 days after final day of participation
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports